Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. This is a different patient population than those being assessed in current clinical trials.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Treatments: Lenograstim; Loratadine

Criteria

Inclusion Criteria:

• Receiving a G-CSF after the institution practice change

• Receiving a G-CSF for one of the following indications:

• Prevention/treatment of neutropenia along with treatment for leukemia or lymphoma

• Mobilization of hematopoietic progenitor cells

• Neutropenia prevention following autologous hematopoietic cell transplant

• Took loratadine per protocol with G-CSF administration

• Completed a survey

Exclusion Criteria:

• Taking daily antihistamines for allergies, asthma, or other indications, not including bone pain

• Taking daily NSAIDs, with the exception of aspirin, for chronic conditions

• Treatment for solid tumor cancers

• Receiving bone modifying agents for bone pain associated with metastatic disease or other chronic conditions